Edition:
United States

Antisense Therapeutics Ltd (ANP.AX)

ANP.AX on Australia Stock Exchange

0.04AUD
24 Mar 2017
Change (% chg)

$0.00 (+12.12%)
Prev Close
$0.03
Open
$0.04
Day's High
$0.04
Day's Low
$0.04
Volume
560,928
Avg. Vol
167,428
52-wk High
$0.06
52-wk Low
$0.03

Latest Key Developments (Source: Significant Developments)

Antisense Therapeutics announces ATL1103 granted orphan drug designation in Europe
Monday, 27 Jun 2016 07:10pm EDT 

Antisense Therapeutics Ltd : ATL1103 granted orphan drug designation in Europe . European commission grants orphan medicinal product designation for acromegaly drug in the European union .  Full Article

Antisense Therapeutics gets orphan drug designation from FDA for ATL1103
Wednesday, 11 May 2016 07:37pm EDT 

Antisense Therapeutics Ltd : Orphan drug designation from FDA for atl1103 in acromegaly Full Article

Antisense Therapeutics intends to seek orphan drug designation for COR-004
Sunday, 9 Aug 2015 07:23pm EDT 

Antisense Therapeutics Ltd:Intends to seek orphan drug designation for COR-004 from the FDA and the EMA.  Full Article

Antisense Therapeutics Ltd announces ownership interest of Cortendo
Monday, 1 Jun 2015 07:49pm EDT 

Antisense Therapeutics Ltd:Says that Cortendo has an interest in 15,025,075 ordinary shares of the company, representing 8.51 pct. of total voting power.  Full Article

Cortendo publ AB and Antisense Therapeutics announce licensing agreement for ATL1103 for Acromegaly
Thursday, 14 May 2015 07:19pm EDT 

Cortendo publ AB and Antisense Therapeutics Ltd:Enter into exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics' ATL1103 for endocrinology applications.Under terms of agreement, Cortendo will provide Antisense Therapeutics with an initial upfront payment of $5 million (A$6.2 million), consisting of $3 million (A$3.7 million) in cash and a $2 million (A$2.5 million) investment in Antisense Therapeutics equity.Says additional payments, contingent upon achieving specific development and commercialization milestones, may total up to $105 million (A$131 million) over lifetime of agreement.Says there is also potential for royalty payments based upon sales performance.  Full Article

Antisense Therapeutics announces new european patent application allowance
Wednesday, 15 Apr 2015 06:57pm EDT 

Antisense Therapeutics Ltd:Says the European Patent Office has allowed European patent application 11194098.7 entitled “Modulation of growth hormone receptor expression and insulin-like growth factor expression.“.European patent covers ANP’s compound ATL1103 to human growth hormone receptor (GHr) in reducing insulin like growth factor 1 (IGF-I) for the treatment of acromegaly and other diseases.  Full Article

More From Around the Web

No consensus analysis data available.